Generics 5

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Nintedanib manufacturers

5 products found

Filters

nintedanib

Capsules 100 mg, 150 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
MA's Granted
Manufacturer #21467

Manufacturer usually replies in 9 days

nintedanib

Capsules 100 mg, 150 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
FDA, EU GMP
Available for
Licensing with supply
Comments
Indication: Idiopathic Pulmonary Fibrosis; Status: MA granted (US), Ongoing Registration (EU)
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 11 days

nintedanib

Oral suspension 50 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #31060

Manufacturer usually replies in nan days

nintedanib

Capsules 100 mg, 150 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #9406

Manufacturer usually replies in 7 days

nintedanib

Capsules 100 mg, 150 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Iraq
Manufacturer #656
It is a fully integrated developer, manufacturer, and marketer of a wide range of soft gelatin formulations, with a strong regulatory and infrastructure back end to support its research and development and global market expansion strategy. The company began licensing and distributing professionally evaluated components and formulations in the OTC and Nutraceutical categories in 2016.

Manufacturer usually replies in 8 days

Nintedanib is a medication used to treat idiopathic pulmonary fibrosis as well as in combination therapies for certain types of non-small-cell lung cancer. The nintedanib suppliers and distributors market it as 100mg and 150mg capsules. The developer and the sole nintedanib manufacturer is Boehringer Ingelheim, who acquired approval to market drug in 2014, under the trade name Ofev (in some countries – Vergatef). Ofev is currently approved in over 70 countries, and due to the ongoing validity of the supplier’s patent, other nintedanib manufacturers have yet to join the market with their formulations. Costs of nintedanib are relatively high and depend on the concentration of the active ingredient. The retail prices per 60 (100mg) capsules fall into an approximate range of 1,000 EUR to 1,200 EUR, whereas the same amount of 150mg capsules cost around 2,000 EUR to 2,250 EUR. Pharmaceutical specialists are welcome to browse through offers of nintedanib capsules for sale from nintedanib suppliers and distributors on our pharmaceutical marketplace, or else seek out further useful medical information about the medication online at the official Ofev website.